Aspirin Report Challenges Dosages For Heart Attacks
On Friday, the FDA denied a request from Bayer Aspirin to change the labeling
on its packaging to market the product for heart attack prevention for patients with no history of cardiovascular disease. Gunderson Health System Dr. Paul Schoenfeld is a cardiologist and agrees with the new report.
Schoenfeld says while evidence shows that aspirin's benefits for people who have already had a cardiovascular event outweigh the increased risk of bleeding, the data doesn't support using the drug to help people prevent a first attack.